Skip to main content

Table 2 Supportive treatments and clinical outcomes between the two groups

From: Invasive pulmonary aspergillosis in immunocompetent patients hospitalised with influenza A-related pneumonia: a multicenter retrospective study

Variables Total (n = 693) IPA group (n = 21) Control group (n = 672) p-valuea
Vasopressor use (n, %) 27 (3.9) 11 (52.4) 16 (2.4) <  0.001
Length of vasopressor use (days, median, IQR) 1.0 (0.5–3.0) 2.0 (0.5–4.5) 1.5 (1.0–2.0) 0.185
Noninvasive ventilation (n, %) 159 (22.9) 9 (42.9) 150 (22.3) 0.014
Length of noninvasive ventilation (days, median, IQR) 4.0 (1.0–8.0) 2.0 (2.0–10.0) 5.0 (1.0–8.0) 0.009
Invasive ventilation (n, %) 158 (22.8) 18 (85.7) 140 (20.8) <  0.001
Length of invasive ventilation (days, median, IQR) 4.0 (1.0–9.0) 9.0 (7.0–11.0) 4.0 (1.0–9.0) 0.003
Complications during hospitalisation (n, %)
 Respiratory failure 167 (24.1) 21 (100.0) 146 (21.7) <  0.001
 Heart failure 147 (21.2) 9 (42.9) 138 (20.5) 0.028
 Septic shock 36 (5.2) 18 (85.7) 18 (2.7) <  0.001
 Acute kidney failure 27 (3.9) 3 (14.3) 24 (3.6) 0.054
 Bloodstream infection 8 (1.2) 0 (0.0) 8 (1.2) > 0.999
Admittance to ICU (n, %) 176 (26.3) 15 (71.4) 161 (24.0) < 0.001
Length of stay in ICU (days, median, IQR) 8.0 (6.0–13.0) 9.0 (7.0–11.0) 8.0 (6.0–13.0) 0.473
LOS (days, median, IQR) 10.0 (8.0–14.0) 24.0 (11.0–42.0) 10.0 (7.0–13.0) < 0.001
60-day mortality (n, %) 136 (19.6) 9 (42.9) 127 (18.9) 0.015
  1. LOS length of stay in hospital, ICU intensive care unit; a: IPA group vs control group. The bolded values are p-values < 0.05, which represent significant differences between subgroups